Michael Higgins
Stock Analyst at Ladenburg Thalmann
(0.59)
# 3,544
Out of 4,666 analysts
24
Total ratings
23.08%
Success rate
-11.84%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNS Marinus Pharmaceuticals | Downgrades: Neutral | n/a | $0.31 | - | 2 | Aug 14, 2024 | |
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $19.79 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $69 | $13.55 | +407.38% | 3 | Apr 8, 2024 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $1.04 | +573.08% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $1.18 | +1,171.19% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $60 | $1.15 | +5,117.39% | 2 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $59.36 | -41.04% | 3 | Mar 2, 2023 | |
| PTN Palatin Technologies | Maintains: Buy | $2 → $50 | $0.91 | +5,369.26% | 1 | Sep 9, 2022 | |
| PHGE BiomX | Maintains: Buy | $130 → $80 | $0.51 | +15,617.09% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | $105 | $8.06 | +1,202.73% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $29 | $36.99 | -21.60% | 2 | Jan 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | n/a | $3.13 | - | 1 | Sep 27, 2017 |
Marinus Pharmaceuticals
Aug 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $19.79
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $13.55
Upside: +407.38%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $1.04
Upside: +573.08%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $1.18
Upside: +1,171.19%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $60
Current: $1.15
Upside: +5,117.39%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $59.36
Upside: -41.04%
Palatin Technologies
Sep 9, 2022
Maintains: Buy
Price Target: $2 → $50
Current: $0.91
Upside: +5,369.26%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.51
Upside: +15,617.09%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $8.06
Upside: +1,202.73%
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $36.99
Upside: -21.60%
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $3.13
Upside: -